Dashboard
Manage Tickers

BMY BRISTOL MYERS SQUIBB CO

NYSE bms.com


$ 46.17 $ 0.00 (0 %)    

Monday, 03-Nov-2025 06:34:16 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
QQQ $ 633.40 $ 0.00 (0 %)
DIA $ 475.98 $ 0.00 (0 %)
SPY $ 684.78 $ 0.00 (0 %)
TLT $ 90.03 $ 0.00 (0 %)
GLD $ 368.50 $ 0.00 (0 %)
$ 46.07
$ 45.40
$ 46.00 x 550
$ 46.31 x 50
-- - --
$ 42.38 - $ 61.00
21,482,913
na
93.79B
$ 0.29
$ 15.53
TBD
na
na ($ 0.05)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 10-30-2025 09-30-2025 10-Q
2 07-31-2025 06-30-2025 10-Q
3 04-24-2025 03-31-2025 10-Q
4 02-12-2025 12-31-2024 10-K
5 10-31-2024 09-30-2024 10-Q
6 07-26-2024 06-30-2024 10-Q
7 04-25-2024 03-31-2024 10-Q
8 02-13-2024 12-31-2023 10-K
9 10-26-2023 09-30-2023 10-Q
10 07-27-2023 06-30-2023 10-Q
11 04-27-2023 03-31-2023 10-Q
12 02-14-2023 12-31-2022 10-K
13 10-26-2022 09-30-2022 10-Q
14 07-27-2022 06-30-2022 10-Q
15 04-29-2022 03-31-2022 10-Q
16 02-09-2022 12-31-2021 10-K
17 10-27-2021 09-30-2021 10-Q
18 07-28-2021 06-30-2021 10-Q
19 04-29-2021 03-31-2021 10-Q
20 02-10-2021 12-31-2020 10-K
21 11-05-2020 09-30-2020 10-Q
22 08-06-2020 06-30-2020 10-Q
23 05-07-2020 03-31-2020 10-Q
24 02-24-2020 12-31-2019 10-K
25 10-31-2019 09-30-2019 10-Q
26 07-25-2019 06-30-2019 10-Q
27 04-25-2019 03-31-2019 10-Q
28 02-25-2019 12-31-2018 10-K
29 10-25-2018 09-30-2018 10-Q
30 07-26-2018 06-30-2018 10-Q
31 04-26-2018 03-31-2018 10-Q
32 02-13-2018 12-31-2017 10-K
33 10-26-2017 09-30-2017 10-Q
34 07-27-2017 06-30-2017 10-Q
35 04-27-2017 03-31-2017 10-Q
36 02-21-2017 12-31-2016 10-K
37 10-27-2016 09-30-2016 10-Q
38 07-28-2016 06-30-2016 10-Q
39 04-28-2016 03-31-2016 10-Q
40 02-12-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

bristol-myers-squibb-launches-7b-debt-buyback-program-to-manage-outstanding-notes
Bristol Myers Squibb Launches $7B Debt Buy...
11/03/2025 10:00:11

Bristol-Myers Squibb Company (NYSE:BMY) ("Bristol Myers Squibb" or the "Offeror"), announced the commencement o...

Core News & Articles
CNBC Halftime Report Final Trades: Rocket ...
10/31/2025 17:02:01

bristol-myers-new-treatments-drive-q3-beat--and-the-companys-raising-its-outlook
Bristol Myers' New Treatments Drive Q3 Bea...
10/30/2025 18:55:45

Bristol Myers beats Q3 forecasts with $12.22 billion revenue and a higher 2025 sales outlook, driven by strong demand for Reblo...

meta-tumbles-10-google-marks-historic-rally-whats-moving-markets-thursday
Meta Tumbles 10%, Google Marks Historic Ra...
10/30/2025 17:40:46

Wall Street saw a cautious tone on Thursday as major tech-heavy indexes edged lower, weighed down by mixed earnings from the me...

Core News & Articles
10 Health Care Stocks Whale Activity In To...
10/30/2025 17:35:24

earnings-scheduled-for-october-30-2025
Earnings Scheduled For October 30, 2025
10/30/2025 11:12:06

bristol-myers-squibb-narrows-fy2025-adj-eps-guidance-from-635-665-to-640-660-vs-638-est-raises-fy2025-sales-guidance-from-46500b-47500b-to-47500b-48000b-vs-47332b-est
Bristol-Myers Squibb Narrows FY2025 Adj EP...
10/30/2025 11:00:20

Bristol-Myers Squibb (NYSE:BMY) narrows FY2025 Adj EPS guidance from $6.35-$6.65 to $6.40-$6.60 vs $6.38 analyst estimate. Rais...

bristol-myers-squibb-q3-adj-eps-163-beats-151-estimate-sales-12222b-beat-11814b-estimate
Bristol-Myers Squibb Q3 Adj. EPS $1.63 Bea...
10/30/2025 10:59:34

Bristol-Myers Squibb (NYSE:BMY) reported quarterly earnings of $1.63 per share which beat the analyst consensus estimate of $1....

what-to-expect-from-bristol-myers-squibbs-earnings
What to Expect from Bristol-Myers Squibb's...
10/29/2025 14:04:34

bristol-myers-squibbs-sotyktu-shows-sustained-efficacy-and-safety-at-week-52-in-poetyk-psa-1-trial
Bristol Myers Squibb's Sotyktu Shows Susta...
10/27/2025 11:01:30

New data from the pivotal Phase 3 POETYK PsA-1 trial demonstrated that Sotyktu improved and maintained meaningful clinical resp...

avidity-shareholders-win-big-as-novartis-moves-fast-on-12-billion-deal
Avidity Shareholders Win Big As Novartis M...
10/27/2025 10:11:40

Avidity Biosciences (NASDAQ: RNA) shares soar as Novartis (NYSE: NVS) agrees to acquire them for $12 billion in cash.

Core News & Articles
Evotec Reports $25M Payment From Bristol M...
10/27/2025 07:06:31

Advances made in preclinical pipeline addressing neurodegenerative diseasesEvotec receives US$ 25 m payment to support continue...

reported-saturday-bristol-myers-squibb-presents-phase-1-breakfree-1-data-showing-cd19-nex-t-car-t-therapy-achieves-94-off-immunosuppressive-therapy-in-autoimmune-diseases
Reported Saturday, Bristol Myers Squibb Pr...
10/27/2025 06:55:50

Positive, early results from 71 patients treated across three disease cohorts – systemic sclerosis, systemic lupus erythematosu...

bristol-myers-squibb-systimmune-present-oral-safety-efficacy-results-from-global-phase-1-us-lung-101-trial-of-iza-bren-to-treat-advanced-solid-tumors-data-revealed-promising-antitumor-activity-across-different-tumor-types-manageable-safety-profile
Bristol Myers Squibb, SystImmune Present O...
10/17/2025 14:06:22

REDMOND, Wash. and PRINCETON, N.J., Oct. 17, 2025 /PRNewswire/ -- SystImmune Inc. (SystImmune), a clinical-stage biotechnology ...

wall-streets-most-accurate-analysts-spotlight-on-3-health-care-stocks-with-over-3-dividend-yields
Wall Street's Most Accurate Analysts Spotl...
10/15/2025 11:15:13

bristol-myers-squibb-and-insitro--announced-the-next-phase-of-their-collaboration-to-discover-new-molecules-with-potential-as-new-treatments-for-amyotrophic-lateral-sclerosis-collaboration-extension-builds-on-5-year-agreement-announced-in-2020
Bristol Myers Squibb And insitro Announce...
10/14/2025 20:03:39

insitro, a pioneer in machine learning–driven drug discovery and development, and Bristol Myers Squibb (NYSE:BMY), today announ...

bristol-myers-squibb-to-present-data-from-over-50-oncology-studies-at-esmo-congress-2025-covering-over-10-cancer-types-across-pipeline-and-portfolio
Bristol Myers Squibb To Present Data From ...
10/13/2025 11:01:32

Bristol Myers Squibb (NYSE:BMY) today announced the presentation of data across its oncology portfolio and pipeline at the Euro...

systimmune-announced-first-patient-dosed-in-ph23-izabright-breast01-trial-of-iza-bren-in-previously-untreated-triple-negative-breast-cancer-250m-milestone-payment-triggered-from-bristol-myers-squibb
SystImmune Announced First Patient Dosed I...
10/13/2025 09:09:42

SystImmune, Inc., a clinical-stage biotechnology company, today announced the treatment of the first patient in the IZABRIGHT-B...

bristol-myers-expands-cell-therapy-portfolio-with-orbital-therapeutics-acquisition
Bristol Myers Expands Cell Therapy Portfol...
10/10/2025 14:32:43

Bristol Myers Squibb is acquiring Orbital Therapeutics for $1.5 billion, expanding its RNA and in vivo CAR T-cell therapy portf...

bristol-myers-squibb-agreed-to-acquire-orbital-therapeutics-a-privately-held-biotechnology-for-15b
Bristol Myers Squibb Agreed To Acquire Orb...
10/10/2025 11:02:15

Acquisition includes OTX-201, an investigational next-generation CAR T-cell therapy designed to reprogram cells in vivo with po...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION